Drug intelligence / Profile preview

AAV2-shmTOR

Development stage
Unknown
Lead developer
Kubota Vision
Modality
Viral Vectors → Gene Addition/Replacement → Gene Therapies, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
Administration
Intravitreal, Subretinal
01

Overview

**AAV2-shmTOR** is an investigational gene therapy designed to target and silence the mammalian target of rapamycin (mTOR) pathway in retinal cells. It utilizes an adeno-associated virus serotype 2 (AAV2) vector to deliver a short hairpin RNA (shRNA) specifically targeting mTOR mRNA, leading to its knockdown via RNA interference. The primary therapeutic goal is neuroprotection and preservation of vision in degenerative retinal diseases, such as geographic atrophy secondary to age-related macular degeneration (AMD). By inhibiting mTOR signaling, the therapy aims to reduce cell death and slow disease progression.

Other names
AAV2-shmTORAAV-2-shmTORAAV 2-shmTOR
02

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on AAV2-shmTOR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV2-shmTOR.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call